title: Recent advances in the development of Aurora kinases inhibitors in hematological malignancies.
abstract: Over the last two decades, since the discovery of Drosophila mutants in 1995, much effort has been made to understand Aurora kinase biology. Three mammalian subtypes have been identified thus far which include the Aurora A, B and C kinases. These regulatory proteins specifically work at the cytoskeleton and chromosomal structures between the kinetochores and have vital functions in the early phases of the mitotic cell cycle. Today, there are multiple phase I and phase II clinical trials as well as numerous preclinical studies taking place looking at Aurora kinase inhibitors in both hematologic and solid malignancies. This review focuses on the preclinical and clinical development of Aurora kinase inhibitors in hematological malignancy and discusses their therapeutic potential.
authors.affiliation: University of Rochester - James P. Wilmot Cancer Center, 601 Elmwood Ave, Rochester NY 14642, USA.
authors.forename: Iqra
authors.initials: I
authors.lastname: Choudary
authors.affiliation: University of Rochester - James P. Wilmot Cancer Center, USA.
authors.forename: Paul M
authors.initials: PM
authors.lastname: Barr
authors.affiliation: University of Rochester - James P. Wilmot Cancer Center, USA.
authors.forename: Jonathan
authors.initials: J
authors.lastname: Friedberg
keywords: Aurora A kinase inhibitor; Aurora B kinase inhibitor; Aurora kinase inhibitors; acute myeloid leukemia; multiple myeloma; non-Hodgkin’s lymphoma